Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange


To evaluate the role of inhaled corticosteroids to suppress nitric oxide gas exchange in stable patients with moderate-to-severe COPD who are current non-smokers and not on oral corticosteroids.

Full Title of Study: “Evaluation of the Effects of Varying Doses of Inhaled Corticosteroids on Suppression of Total Exhaled, Bronchial, and Alveolar Nitric Oxide as Markers of Endogenous Inflammation in Patients With Moderate-to-severe COPD”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: October 2013

Detailed Description

Stable, non-smoking COPD patients not on oral corticosteroids will be randomized in single blinded study to evaluate nitric oxide gas exchange at baseline, and subsequent effects of fluticasone 100mcg/salmeterol 50mcg bid, and fluticasone 250mcg/salmeterol 50mcg bid. Primary end points will include measurements of nitric oxide at varying expiratory flow rates to calculate bronchial, and small airway/alveolar nitric oxide. Secondary end points will evaluate lung function. Exhaled nitric oxide production presumably reflects endogenous inflammation. Normal healthy, non-smoking controls will be used for comparison, with exhaled nitric oxide measured before and after 3 weeks of low dose inhlaed corticosteroids.


  • Drug: fluticasone 100mcg/ salmeterol 50mcg
    • inhaled fluticasone 100mcg/salmeterol 50mcg bid X 3 months
  • Drug: fluticasone 250/salmeterol 50
    • inhaled fluticasone 250/salmeterol 50 X 3 months to evaluate effect on lung function and exhaled nitric oxide
  • Drug: salmeterol
    • salmeterol 50 mcg by dry powder inhaler disk bid to evaluated effect on lung function and exhaled nitric oxide
  • Drug: Salmeterol
    • salmeterol 50mcg bid X 3months
  • Drug: salmeterol and fluticasone propionate
    • salmeterol 50mcg/fluticasone 250mcg by DPI bid

Arms, Groups and Cohorts

  • long acting bronchodilator
    • salmeterol 50mcg bid by DPI, no fluticasone in patients with COPD/emphysema to evaluate effect on bronchodilation and exhaled nitric oxide
  • bronchodilator/ inhaled corticosteroid
    • fluticasone 250mcg/salmeterol 50 mcg bid X 3momths to evaluate effect on lung function and exhaled nitric oxide
  • C
    • Fluticasone 100mcg/salmeterol 50mcg

Clinical Trial Outcome Measures

Primary Measures

  • total exhaled, bronchial, and small airway/alveolar nitric oxide
    • Time Frame: 3 months

Secondary Measures

  • lung function
    • Time Frame: 3 months

Participating in This Clinical Trial

Inclusion Criteria

  • Clinical diagnosis of copd
  • Current non-smoker
  • Not on oral corticosteroids
  • Must be able to use Advair discus or salmeterol discus

Exclusion Criteria

  • Pregnancy
  • Current smoker
  • On corticosteroids
  • Clinically unstable

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: 85 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Arthur F Gelb MD
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Arthur F Gelb MD, Arthur F Gelb MD – Gelb, Arthur F., M.D.
  • Overall Official(s)
    • Arthur F Gelb, MD, Principal Investigator, Arthur F Gelb Medical Corporation

Citations Reporting on Results

Gelb AF, Flynn Taylor C, Shinar C. Nitric Oxide gas exchange in COPD. Am J Respir Crit Care Med 2007; 174: A630.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.